PA Resources Portlet

Resources

CODING & DOCUMENTATION

EDUCATION & EVENTS

ENROLLMENT & CREDENTIALING

FORMS & MANUALS

HEALTHCARE INFORMATION & TECHNOLOGY

PATIENT HEALTH

PHARMACY

POLICIES & GUIDELINES

PRE-SERVICE REVIEW

PROGRAMS & INITIATIVES

PROVIDER NETWORKS & SPECIALTIES

PA Dynamic Rendering

Back

COVID-19 Vaccine Codes - April 18, 2023 FDA Updates

Back to COVID-19 Vaccines page

COVID-19 Vaccine Code Updates

On April 18, 2023, the U.S. Food and Drug Administration (FDA) updated its recommendations for COVID-19 vaccines, authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for ALL doses administered to individuals 6 months of age and older, including additional doses for certain populations. 

Bivalent Vaccine CPT Code Vaccine Name Vaccine Administration Codes  
91312: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Pfizer COVID-19 Bivalent Vaccine (Ages 12 years and older)

 

0121A: First Dose

0124A: Additional  Dose

91313: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Moderna COVID-19 Bivalent Vaccine (Ages 12 years and older)  0134A: Additional  Dose
91314: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Moderna COVID-19 Bivalent Vaccine (Ages 6 months through 11 years)

0141A: First Dose

0142A: Second Dose

0144A: Additional  Dose

91315: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Pfizer COVID-19 Bivalent Vaccine (Ages 5 through 11 years) 

0154A: First Dose

0154A: Single Dose

91316: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Moderna COVID-19 Bivalent Vaccine (Ages 6 months through 5 years)  0164A: Additional  Dose
91317: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Pfizer COVID-19 Bivalent Vaccine (Ages 6 months through 4 years) 

0171A: First Dose

0172A: Second Dose

0173A: Third Dose

0174A: Additional Dose

 

Effective April 18, 2023, the FDA EUA update rescinded use of the following monovalent vaccines: 

Monovalent Vaccine CPT Code Vaccine Name Vaccine Administration Codesthe   
91300: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use Pfizer-BioNTech COVID-19 Vaccine (Ages 12 years and older)

0001A: First Dose
0002A: Second Dose
0003A: Third Dose
0004A: Booster Dose

91301: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use Moderna COVID-19 Vaccine (Ages 12 years and older)

0011A: First Dose
0012A: Second Dose
0013A: Third Dose

91303: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use Janssen COVID-19 Vaccine (Ages 18 years and older)

0031A: Single Dose
0034A: Booster Dose

91304: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use Novavax COVID-19 Vaccine, Adjuvanted (Ages 12 years and older)

0041A: First Dose
0042A: Second Dose
0044A: Booster Dose (Ages 18 and older)

91305: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Pfizer COVID-19 Vaccine (Ages 12 years and older)

0051A: First Dose
0052A: Second Dose
0053A: Third Dose
0054A: Booster Dose

91306: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use Moderna COVID-19 Vaccine (Low Dose)

0064A: Booster Dose

91307: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Pfizer-BioNTech COVID-19 Pediatric Vaccine (Ages 5  through 11 years)

0071A: First Dose
0072A: Second Dose
0073A: Third Dose
0074A: Booster Dose

91308: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Pfizer COVID-19 Vaccine (Ages 6 months through 4 years)

0081A: First Dose
0082A: Second Dose
0083A: Third Dose

91309: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Moderna COVID-19 Vaccine (Ages 6  through 11 years)

0091A: First Dose
0092A: Second Dose
0093A: Third Dose

91311: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Moderna COVID-19 Pediatric Vaccine (Ages 6 months through 5 years)

0111A: First Dose
0112A: Second Dose
0113A: Third Dose